Multicenter phase II study of CyclOBEAP regimen for elderly patients with poor-prognosis aggressive lymphoma

We treated elderly patients (65-69 years) who had aggressive lymphoma with the CyclOBEAP regimen, and we studied the safety and efficacy of this treatment The CyclOBEAP regimen was administered over a total period of 12 weeks. Doxorubicin 40 mg/m² was given every 2 weeks in combination with either cyclophosphamide 800 mg/m² or etoposide 70 mg/m² qd × 3. During the alternate weeks, non-myelosuppressive vincristine 1.0 mg/m² was given either with bleomycin 10 mg/m² or alone. Prednisolone 40 mg/m² was administered daily for three 14-day periods during weeks 1-2, 5-6 and 9-10. There were 51 eligible patients. A complete response was achieved in 42 patients (82%). The 5-year overall survival (OS) rate was 60.6% and progression-free survival (PFS) rate was 51.8%. WHO grade 4 neutropenia was observed in 32 patients and thrombocytopenia in 8 patients. We showed that the CyclOBEAP regimen can be safely used in the treatment of aggressive lymphoma in elderly patients and it achieved a high rate of remission.